ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Active:	Yes
Cancer Type:	Breast Cancer	NCT ID:	NCT04829604
Trial Phases:	Phase II	Protocol IDs:	ACE-Breast-03 (primary) NCI-2021-09194
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Ambrx, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04829604

Summary

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were
previously treated with T-DXd

Objectives

A Global, Single Arm, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer
Patients who were previously treated with T-DXd. The ARX788 will be administered every 3
weeks (Q3W) intravenous (IV) infusion.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.